Royalty Pharma Competitors

Royalty Pharma (NASDAQ:RPRX) and Johnson & Johnson (NYSE:JNJ) are both large-cap finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Analyst Ratings

This is a summary of current ratings and recommmendations for Royalty Pharma and Johnson & Johnson, as reported by MarketBeat.

Royalty Pharma presently has a consensus target price of $51.8750, suggesting a potential upside of 22.61%. Johnson & Johnson has a consensus target price of $180.6429, suggesting a potential upside of 12.03%. Given Royalty Pharma's higher probable upside, equities research analysts plainly believe Royalty Pharma is more favorable than Johnson & Johnson.

Profitability

This table compares Royalty Pharma and Johnson & Johnson's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Royalty Pharma and Johnson & Johnson's gross revenue, earnings per share (EPS) and valuation.

Johnson & Johnson has higher revenue and earnings than Royalty Pharma.

Dividends

Royalty Pharma pays an annual dividend of $0.68 per share and has a dividend yield of 1.6%. Johnson & Johnson pays an annual dividend of $4.04 per share and has a dividend yield of 2.5%. Johnson & Johnson pays out 46.5% of its earnings in the form of a dividend. Royalty Pharma has increased its dividend for 1 consecutive years and Johnson & Johnson has increased its dividend for 59 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Insider & Institutional Ownership

40.9% of Royalty Pharma shares are held by institutional investors. Comparatively, 67.3% of Johnson & Johnson shares are held by institutional investors. 2.5% of Royalty Pharma shares are held by insiders. Comparatively, 0.3% of Johnson & Johnson shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Johnson & Johnson beats Royalty Pharma on 9 of the 12 factors compared between the two stocks.

Royalty Pharma (NASDAQ:RPRX) and Pfizer (NYSE:PFE) are both large-cap finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Analyst Ratings

This is a summary of current ratings and recommmendations for Royalty Pharma and Pfizer, as reported by MarketBeat.

Royalty Pharma presently has a consensus target price of $51.8750, suggesting a potential upside of 22.61%. Pfizer has a consensus target price of $38.5714, suggesting a potential upside of 5.39%. Given Royalty Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Royalty Pharma is more favorable than Pfizer.

Profitability

This table compares Royalty Pharma and Pfizer's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Royalty Pharma and Pfizer's gross revenue, earnings per share (EPS) and valuation.

Pfizer has higher revenue and earnings than Royalty Pharma.

Dividends

Royalty Pharma pays an annual dividend of $0.68 per share and has a dividend yield of 1.6%. Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 4.3%. Pfizer pays out 52.9% of its earnings in the form of a dividend. Royalty Pharma has increased its dividend for 1 consecutive years and Pfizer has increased its dividend for 1 consecutive years.

Insider & Institutional Ownership

40.9% of Royalty Pharma shares are held by institutional investors. Comparatively, 67.4% of Pfizer shares are held by institutional investors. 2.5% of Royalty Pharma shares are held by insiders. Comparatively, 0.1% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Pfizer beats Royalty Pharma on 6 of the 11 factors compared between the two stocks.

Royalty Pharma (NASDAQ:RPRX) and Merck & Co., Inc. (NYSE:MRK) are both large-cap finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Analyst Ratings

This is a summary of current ratings and recommmendations for Royalty Pharma and Merck & Co., Inc., as reported by MarketBeat.

Royalty Pharma presently has a consensus target price of $51.8750, suggesting a potential upside of 22.61%. Merck & Co., Inc. has a consensus target price of $95.9167, suggesting a potential upside of 25.69%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, analysts plainly believe Merck & Co., Inc. is more favorable than Royalty Pharma.

Profitability

This table compares Royalty Pharma and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Royalty Pharma and Merck & Co., Inc.'s gross revenue, earnings per share (EPS) and valuation.

Merck & Co., Inc. has higher revenue and earnings than Royalty Pharma.

Dividends

Royalty Pharma pays an annual dividend of $0.68 per share and has a dividend yield of 1.6%. Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.4%. Merck & Co., Inc. pays out 50.1% of its earnings in the form of a dividend. Royalty Pharma has increased its dividend for 1 consecutive years and Merck & Co., Inc. has increased its dividend for 1 consecutive years.

Insider & Institutional Ownership

40.9% of Royalty Pharma shares are held by institutional investors. Comparatively, 72.9% of Merck & Co., Inc. shares are held by institutional investors. 2.5% of Royalty Pharma shares are held by insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Merck & Co., Inc. beats Royalty Pharma on 9 of the 11 factors compared between the two stocks.

Royalty Pharma (NASDAQ:RPRX) and AbbVie (NYSE:ABBV) are both large-cap finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Analyst Ratings

This is a summary of current ratings and recommmendations for Royalty Pharma and AbbVie, as reported by MarketBeat.

Royalty Pharma presently has a consensus target price of $51.8750, suggesting a potential upside of 22.61%. AbbVie has a consensus target price of $115.75, suggesting a potential upside of 7.63%. Given Royalty Pharma's higher probable upside, equities research analysts plainly believe Royalty Pharma is more favorable than AbbVie.

Profitability

This table compares Royalty Pharma and AbbVie's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Royalty Pharma and AbbVie's gross revenue, earnings per share (EPS) and valuation.

AbbVie has higher revenue and earnings than Royalty Pharma.

Dividends

Royalty Pharma pays an annual dividend of $0.68 per share and has a dividend yield of 1.6%. AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.8%. AbbVie pays out 58.2% of its earnings in the form of a dividend. Royalty Pharma has increased its dividend for 1 consecutive years and AbbVie has increased its dividend for 49 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Insider & Institutional Ownership

40.9% of Royalty Pharma shares are held by institutional investors. Comparatively, 67.5% of AbbVie shares are held by institutional investors. 2.5% of Royalty Pharma shares are held by insiders. Comparatively, 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

AbbVie beats Royalty Pharma on 9 of the 12 factors compared between the two stocks.

Royalty Pharma (NASDAQ:RPRX) and Eli Lilly and (NYSE:LLY) are both large-cap finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Dividends

Royalty Pharma pays an annual dividend of $0.68 per share and has a dividend yield of 1.6%. Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.8%. Eli Lilly and pays out 56.3% of its earnings in the form of a dividend. Royalty Pharma has increased its dividend for 1 consecutive years and Eli Lilly and has increased its dividend for 1 consecutive years.

Insider & Institutional Ownership

40.9% of Royalty Pharma shares are held by institutional investors. Comparatively, 75.6% of Eli Lilly and shares are held by institutional investors. 2.5% of Royalty Pharma shares are held by insiders. Comparatively, 0.1% of Eli Lilly and shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Royalty Pharma and Eli Lilly and's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings and recommmendations for Royalty Pharma and Eli Lilly and, as reported by MarketBeat.

Royalty Pharma presently has a consensus target price of $51.8750, suggesting a potential upside of 22.61%. Eli Lilly and has a consensus target price of $196.40, suggesting a potential upside of 6.46%. Given Royalty Pharma's higher probable upside, equities research analysts plainly believe Royalty Pharma is more favorable than Eli Lilly and.

Earnings and Valuation

This table compares Royalty Pharma and Eli Lilly and's gross revenue, earnings per share (EPS) and valuation.

Eli Lilly and has higher revenue and earnings than Royalty Pharma.

Summary

Eli Lilly and beats Royalty Pharma on 8 of the 11 factors compared between the two stocks.

Royalty Pharma (NASDAQ:RPRX) and Bristol-Myers Squibb (NYSE:BMY) are both large-cap finance companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Dividends

Royalty Pharma pays an annual dividend of $0.68 per share and has a dividend yield of 1.6%. Bristol-Myers Squibb pays an annual dividend of $1.96 per share and has a dividend yield of 3.1%. Bristol-Myers Squibb pays out 41.8% of its earnings in the form of a dividend. Royalty Pharma has raised its dividend for 1 consecutive years and Bristol-Myers Squibb has raised its dividend for 1 consecutive years.

Institutional & Insider Ownership

40.9% of Royalty Pharma shares are owned by institutional investors. Comparatively, 72.4% of Bristol-Myers Squibb shares are owned by institutional investors. 2.5% of Royalty Pharma shares are owned by company insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Royalty Pharma and Bristol-Myers Squibb's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings for Royalty Pharma and Bristol-Myers Squibb, as reported by MarketBeat.com.

Royalty Pharma currently has a consensus target price of $51.8750, suggesting a potential upside of 22.61%. Bristol-Myers Squibb has a consensus target price of $74.6429, suggesting a potential upside of 19.22%. Given Royalty Pharma's higher probable upside, research analysts clearly believe Royalty Pharma is more favorable than Bristol-Myers Squibb.

Valuation & Earnings

This table compares Royalty Pharma and Bristol-Myers Squibb's revenue, earnings per share (EPS) and valuation.

Bristol-Myers Squibb has higher revenue and earnings than Royalty Pharma.

Summary

Bristol-Myers Squibb beats Royalty Pharma on 8 of the 12 factors compared between the two stocks.